Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation
- PMID: 18984974
- DOI: 10.1159/000163034
Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation
Abstract
Hypothesis: The combination of chemotherapy and radiotherapy is a standard nonsurgical treatment for locally advanced laryngeal cancer. Nevertheless, there are no validated markers to predict the outcome of nonsurgical therapies. The impact of previous tracheotomy is not clear in patients submitted to concomitant chemoradiotherapy.
Study design: A non-randomized prospective study. Prognostic factors such as stage, age, performance status, number of chemotherapy cycles, radiotherapy dose, stage VIb disease, and previous tracheotomy were analyzed using the Cox's proportional hazard model. The Kaplan-Meier and log rank tests were used to evaluate the progression-free and overall survival.
Patients and methods: Patients with stage III/IV laryngeal carcinoma were prospectively selected. Treatment consisted of cisplatin 100 mg/m(2) every 3 weeks for 3 cycles, radiotherapy to a total dose of 70.2 Gy and salvage surgery.
Results: Forty-nine patients were analyzed; tracheotomy was performed in 12 patients (24.5%) before therapy. Patients who had previous tracheotomy had a lower rate of complete response (41.7 vs. 75%, p = 0.034, HR 0.55, CI 95% 0.27-1.11), shorter progression free-survival (HR 2.83, CI 95% 1.60-4.88, p < 0.001), and median overall survival (12 vs. 56 months, HR 2.37, CI 95% 1.43-3.93, p < 0.001), in comparison to those without a tracheotomy. Moreover a significant difference was observed in 3-year survival rates (6 vs. 61%, p = 0.001), in favor of the group without tracheotomy. Interestingly, the impact of previous tracheotomy was not altered when adjusted by other prognostic factors (HR 8.7, CI 95% 3.1-24.0, p < 0.001).
Conclusions: Previous tracheotomy is a negative prognostic factor for patients submitted to chemotherapy combined with radiotherapy and should be considered as a negative clinical prognostic factor in the selection of patients for more aggressive treatment strategies.
Copyright 2008 S. Karger AG, Basel.
Similar articles
-
The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer.J Urol. 2008 Nov;180(5):2019-23. doi: 10.1016/j.juro.2008.07.040. Epub 2008 Sep 17. J Urol. 2008. PMID: 18801542
-
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.Gynecol Oncol. 2007 Nov;107(2):285-91. doi: 10.1016/j.ygyno.2007.06.014. Epub 2007 Aug 6. Gynecol Oncol. 2007. PMID: 17688923
-
Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma.Laryngoscope. 2002 May;112(5):844-51. doi: 10.1097/00005537-200205000-00013. Laryngoscope. 2002. PMID: 12150616 Clinical Trial.
-
Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1293-303. doi: 10.1016/j.ijrobp.2008.10.047. Int J Radiat Oncol Biol Phys. 2009. PMID: 19306746
-
Combined modality treatment of laryngeal squamous cell carcinoma.Expert Rev Anticancer Ther. 2007 Mar;7(3):331-50. doi: 10.1586/14737140.7.3.331. Expert Rev Anticancer Ther. 2007. PMID: 17338653 Review.
Cited by
-
Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis.Eur Arch Otorhinolaryngol. 2011 Feb;268(2):165-79. doi: 10.1007/s00405-010-1395-8. Epub 2010 Oct 19. Eur Arch Otorhinolaryngol. 2011. PMID: 20957488
-
[Larynx preservation: recommendations for decision-making in T3 laryngeal cancer patients].HNO. 2022 Aug;70(8):581-587. doi: 10.1007/s00106-022-01177-7. Epub 2022 May 16. HNO. 2022. PMID: 35575826 Free PMC article. German.
-
Functional outcomes after chemoradiotherapy of laryngeal and pharyngeal cancers.Curr Oncol Rep. 2012 Apr;14(2):158-65. doi: 10.1007/s11912-012-0216-1. Curr Oncol Rep. 2012. PMID: 22249533 Free PMC article. Review.
-
Chemoradiotherapy but Not Radiotherapy Alone for Larynx Preservation in T3. Considerations from a German Observational Cohort Study.Cancers (Basel). 2021 Jul 8;13(14):3435. doi: 10.3390/cancers13143435. Cancers (Basel). 2021. PMID: 34298650 Free PMC article.
-
Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.Oncologist. 2017 Sep;22(9):1056-1066. doi: 10.1634/theoncologist.2017-0015. Epub 2017 May 22. Oncologist. 2017. PMID: 28533474 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical